TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06504732: A Phase II/III Clinical Study Evaluating IAH0968 in Combination or Not in Combination With the CAPEOX Regimen in HER2-expressing Advanced/Metastatic Solid Tumors and Gastric Cancer

Sponsor: SUNHO（China）BioPharmaceutical CO., Ltd. · Phase: PHASE2/PHASE3 · Area: ONCOLOGY · Target Enrollment: 574 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$18,036,480

Rescue Site Savings

+$11,892,804

Unlock Full NCT06504732 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06504732 Rescue Dossier →